

Supplemental Material

491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514

More Details Can Be Found At: <http://www.neurosurg.cam.ac.uk/pages/ICM/about.php>

Autoregulation Signal Acquisition and Processing Methods


Transcranial Doppler (TCD) monitoring (DWL, Compumedics DWL, El Paso, TX) of the right and left MCA was performed with two 2.5-MHz transducers fitted on a headband and positioned over the temporal bone windows to obtain bilateral continuous measurement of baseline velocity. Depth of insonation was varied between 35 and 52 mm until representative spectral MCA flow is identified then the transducers are locked in that position. Arterial pressure data (from an indwelling cannula placed for clinical purposes) was obtained from the operating room hemodynamic monitor via the analog output port. The arterial blood pressure data and the TCD signals were sampled at 58 Hz with an analog-to-digital converter and then imported into a laptop computer using ICM+ software (University of Cambridge, Cambridge, UK).¹⁻⁷ This proprietary software collects and integrates high resolution, multimodal data for real-time analysis of intracranial pressure, arterial pressure, brain oxygenation, blood flow, and other signals allowing for calculation of various physiological indices include autoregulation metrics (<https://www.enterprise.cam.ac.uk/opportunities/icm-software-for-brain-monitoring-in-neurological-intensive-care-research/>).

Blood pressure and TCD signals are time-integrated as non-overlapping 10-sec mean values, equivalent to applying a moving average filter with a 10-sec time window and resampling at 0.1 Hz. This operation eliminates high-frequency noise from the respiratory and pulse frequencies, according to the Nyquist theorem, allowing detection of oscillations and transients that occur below 0.05 Hz. A continuous, moving Pearson's correlation

515 coefficient is calculated between MAP and TCD cerebral blood flow velocity, rendering
516 the variable mean velocity index (Mx). Consecutive, paired, 10-sec averaged values from
517 300 sec duration are used for each calculation, incorporating 30 data points as we have
518 reported.^{8,9} Mx values for each patient are placed into 5 mmHg MAP bins and displayed
519 on the laptop computer (**Fig 1**). When MAP is within the limits of CBF autoregulation Mx
520 approach zero; when MAP is outside the limits of autoregulation, Mx approaches 1,
521 indicating that CBF is blood pressure dependent.

522 Based on our prior studies, we designate the LLA as the highest blood pressure
523 associated with $Mx \geq 0.4$. These values are within the range found to be associated with
524 poor outcome after traumatic brain injury and adverse outcomes after cardiac surgery.¹⁰⁻¹³
525 In about 20% of patients, impaired autoregulation is observed when Mx are ≥ 0.4 at all
526 MAPs during CPB. An attenuated autoregulation plateau is usually observed. Thus, the
527 “optimal” MAP, defined as the MAP with the lowest Mx, as this point is observed in
528 patients with functional and impaired autoregulation. As blood pressure varies during the
529 usual course of surgery, including during the initiation of CPB, no specific interventions
530 are needed to establish autoregulation indices.

531



532

533 **Figure.** Graph of autoregulation data obtained in the operating room during
 534 cardiopulmonary bypass. The top graph is the time series of blood pressure. The middle
 535 two bar graphs represent autoregulation data from the left and right sides, respectively,
 536 placed into 5 mmHg arterial blood pressure (ABP) bins. The bottom histogram represents
 537 the percentage of the time of the recording spent at each ABP bin. The autoregulation
 538 variable is a dimensionless correlation coefficient between cerebral blood flow velocity and
 539 ABP, mean velocity index (Mx). An Mx approaching 1 represents impairment of
 540 autoregulation while Mx close to zero represents functional autoregulation. The red short
 541 arrow represents the lower limit of autoregulation defined in this analysis as that ABP were
 542 Mx increases from < 0.4 to ≥ 0.4 . The thick black arrow indicates optimal ABP defined as
 543 that ABP with the lowest Mx.

544

545

546 References:

- 547 1. Steiner L, Coles J, Johnston A, Chatfield D, Smielewski P, Fryer T, Aigbirhio F,
 548 Clark J, Pickard J, Menon D, Czosnyka M. Assessment of cerebrovascular
 549 autoregulation in head-injured patients: a validation study. *Stroke*. 2003;34:2404-
 550 2409.
- 551 2. Lang EW, Mehdorn HM, Dorsch NW, Czosnyka M. Continuous monitoring of
 552 cerebrovascular autoregulation: a validation study. *J Neurol Neurosurg Psychiatry*.
 553 2002;72:583-586.
- 554 3. Steiner LA, Czosnyka M, Piechnik SK, Smielewski P, Chatfield D, Menon DK,
 555 Pickard JD. Continuous monitoring of cerebrovascular pressure reactivity allows
 556 determination of optimal cerebral perfusion pressure in patients with traumatic
 557 brain injury. *Crit Care Med*. 2002;30(4):733-738.
- 558 4. Reinhard M, Roth M, Muller T, Guschlbauer B, Timmer J, Czosnyka M, Hetzel A.
 559 Effect of carotid endarterectomy or stenting on impairment of dynamic cerebral

- 560 autoregulation. *Stroke*. 2004;35:1381-1387.
- 561 5. Minhas PS, Smielewski P, Kirkpatrick PJ, Pickard JD, Czosnyka M. Pressure
562 autoregulation and positron emission tomography-derived cerebral blood flow
563 acetazolamide reactivity in patients with carotid artery stenosis. *Neurosurg*
564 2004;55:63-68.
- 565 6. Reinhard M, Roth M, Guschlbauer B, Harloff A, Timmer J, Czosnyka M, Hetzel A.
566 Dynamic cerebral autoregulation in acute ischemic stroke assessed from
567 spontaneous blood pressure fluctuations. *Stroke*. 2005;36:1684-1689.
- 568 7. Lavinio A, Schmidt E, Haubrich C, Smielewski P, Pickard JD, Czosnyka M.
569 Noninvasive evaluation of dynamic cerebrovascular autoregulation using Finapres
570 plethysmograph and transcranial Doppler. *Stroke*. 2007;38:402-404.
- 571 8. Brady KM, Lee JK, Kibler KK, Smielewski P, Czosnyka M, Easley RB, Koehler
572 RC, Shaffner DH. Continuous time-domain analysis of cerebrovascular
573 autoregulation using near-infrared spectroscopy. *Stroke; a journal of cerebral*
574 *circulation*. 2007;38:2818-2825.
- 575 9. Brady K, Joshi B, Zweifel C, Smielewski P, Czosnyka M, Easley B, Hogue J, C.W.
576 Real time continuous monitoring of cerebral blood flow autoregulation using near-
577 infrared spectroscopy in patients undergoing cardiopulmonary bypass. *Stroke; a*
578 *journal of cerebral circulation*. 2010;41:1951-1956.
- 579 10. Blauth C, Schulenberg W, McCartney A, Taylor K, Loop F. Retinal microvascular
580 studies in vivo with fluorescein angiography. *J Thorac Cardiovasc Surg*
581 1988;95:668-676.
- 582 11. Schell R, Kern F, Greeley W, Schulman S, Frasco P, Croughwell N, Newman M,
583 Reves J. Cerebral blood flow and metabolism during cardiopulmonary bypass.
584 *Anesth Analg* 1993;76:849-865.
- 585 12. Ono M, Arnaoutakis GJ, Fine DM, Brady K, Easley RB, Zheng Y, Brown C, Katz
586 NM, Grams ME, Hogue CW. Blood Pressure Excursions Below the Cerebral
587 Autoregulation Threshold During Cardiac Surgery are Associated With Acute
588 Kidney Injury*. *Crit Care Med*. 2013;41(2):464-471.
- 589 13. Ono M, Brady K, Easley R, Brown C, Kraut M, Gottesman R, Hogue CW. Duration
590 and Magnitude of Blood Pressure Below Cerebral Autoregulation Threshold During
591 Cardiopulmonary Bypass Is Associated With Major Morbidity And Operative
592 Mortality. *J Thorac Cardiovasc Surg*. 2013;(in press).
- 593
- 594
- 595
- 596



AMERICAN ASSOCIATION
FOR THORACIC SURGERY

We Model Excellence

**35. Optimal Blood Pressure during
Cardiopulmonary Bypass defined by Cerebral
Autoregulation Monitoring and its
association with Severe Coronary Artery
Disease**

**Presented By:
Daijiro Hori**

AATS 96th Annual Meeting □ Baltimore, Maryland □ aats.org



Supplemental Material

More Details Can Be Found At: <http://www.neurosurg.cam.ac.uk/pages/ICM/about.php>

Autoregulation Signal Acquisition and Processing Methods

Transcranial Doppler (TCD) monitoring (DWL, Compumedics DWL, El Paso, TX) of the right and left MCA was performed with two 2.5-MHz transducers fitted on a headband and positioned over the temporal bone windows to obtain bilateral continuous measurement of baseline velocity. Depth of insonation was varied between 35 and 52 mm until representative spectral MCA flow is identified then the transducers are locked in that position. Arterial pressure data (from an indwelling cannula placed for clinical purposes) was obtained from the operating room hemodynamic monitor via the analog output port. The arterial blood pressure data and the TCD signals were sampled at 58 Hz with an analog-to-digital converter and then imported into a laptop computer using ICM+ software (University of Cambridge, Cambridge, UK).¹⁻⁷ This proprietary software collects and integrates high resolution, multimodal data for real-time analysis of intracranial pressure, arterial pressure, brain oxygenation, blood flow, and other signals allowing for calculation of various physiological indices include autoregulation metrics (<https://www.enterprise.cam.ac.uk/opportunities/icm-software-for-brain-monitoring-in-neurological-intensive-care-research/>).

Blood pressure and TCD signals are time-integrated as non-overlapping 10-sec mean values, equivalent to applying a moving average filter with a 10-sec time window and resampling at 0.1 Hz. This operation eliminates high-frequency noise from the respiratory and pulse frequencies, according to the Nyquist theorem, allowing detection of oscillations and transients that occur below 0.05 Hz. A continuous, moving Pearson's correlation coefficient is calculated between MAP and TCD cerebral blood flow velocity, rendering the variable mean velocity index (Mx). Consecutive, paired, 10-sec averaged values from 300 sec duration are used for each calculation, incorporating 30 data points as we have reported.^{8,9} Mx values for each patient are placed into 5 mmHg MAP bins and displayed on the laptop computer (**Fig 1**). When MAP is within the limits of CBF autoregulation Mx approach zero; when MAP is outside the limits of autoregulation, Mx approaches 1, indicating that CBF is blood pressure dependent.

Based on our prior studies, we designate the LLA as the highest blood pressure associated with $Mx \geq 0.4$. These values are within the range found to be associated with poor outcome after traumatic brain injury and adverse outcomes after cardiac surgery.¹⁰⁻¹³ In about 20% of patients, impaired autoregulation is observed when Mx are ≥ 0.4 at all MAPs during CPB. An attenuated autoregulation plateau is usually observed. Thus, the "optimal" MAP, defined as the MAP with the lowest Mx, as this point is observed in patients with functional and impaired autoregulation. As blood pressure varies during the usual course of surgery, including during the initiation of CPB, no specific interventions are needed to establish autoregulation indices.




Figure. Graph of autoregulation data obtained in the operating room during cardiopulmonary bypass. The top graph is the time series of blood pressure. The middle two bar graphs represent autoregulation data from the left and right sides, respectively, placed into 5 mmHg arterial blood pressure (ABP) bins. The bottom histogram represents the percentage of the time of the recording spent at each ABP bin. The autoregulation variable is a dimensionless correlation coefficient between cerebral blood flow velocity and ABP, mean velocity index (Mx). An Mx approaching 1 represents impairment of autoregulation while Mx close to zero represents functional autoregulation. The red short arrow represents the lower limit of autoregulation defined in this analysis as that ABP were Mx increases from < 0.4 to ≥ 0.4 . The thick black arrow indicates optimal ABP defined as that ABP with the lowest Mx.

References:

1. Steiner L, Coles J, Johnston A, Chatfield D, Smielewski P, Fryer T, Aigbirhio F, Clark J, Pickard J, Menon D, Czosnyka M. Assessment of cerebrovascular autoregulation in head-injured patients: a validation study. *Stroke*. 2003;34:2404-2409.
2. Lang EW, Mehdorn HM, Dorsch NW, Czosnyka M. Continuous monitoring of cerebrovascular autoregulation: a validation study. *J Neurol Neurosurg Psychiatry*. 2002;72:583-586.
3. Steiner LA, Czosnyka M, Piechnik SK, Smielewski P, Chatfield D, Menon DK, Pickard JD. Continuous monitoring of cerebrovascular pressure reactivity allows determination of

- optimal cerebral perfusion pressure in patients with traumatic brain injury. *Crit Care Med.* 2002;30(4):733-738.
4. Reinhard M, Roth M, Muller T, Guschlbauer B, Timmer J, Czosnyka M, Hetzel A. Effect of carotid endarterectomy or stenting on impairment of dynamic cerebral autoregulation. *Stroke.* 2004;35:1381-1387.
 5. Minhas PS, Smielewski P, Kirkpatrick PJ, Pickard JD, Czosnyka M. Pressure autoregulation and positron emission tomography-derived cerebral blood flow acetazolamide reactivity in patients with carotid artery stenosis. *Neurosurg* 2004;55:63-68.
 6. Reinhard M, Roth M, Guschlbauer B, Harloff A, Timmer J, Czosnyka M, Hetzel A. Dynamic cerebral autoregulation in acute ischemic stroke assessed from spontaneous blood pressure fluctuations. *Stroke.* 2005;36:1684-1689.
 7. Lavinio A, Schmidt E, Haubrich C, Smielewski P, Pickard JD, Czosnyka M. Noninvasive evaluation of dynamic cerebrovascular autoregulation using Finapres plethysmograph and transcranial Doppler. *Stroke.* 2007;38:402-404.
 8. Brady KM, Lee JK, Kibler KK, Smielewski P, Czosnyka M, Easley RB, Koehler RC, Shaffner DH. Continuous time-domain analysis of cerebrovascular autoregulation using near-infrared spectroscopy. *Stroke; a journal of cerebral circulation.* 2007;38:2818-2825.
 9. Brady K, Joshi B, Zweifel C, Smielewski P, Czosnyka M, Easley B, Hogue J, C.W. Real time continuous monitoring of cerebral blood flow autoregulation using near-infrared spectroscopy in patients undergoing cardiopulmonary bypass. *Stroke; a journal of cerebral circulation.* 2010;41:1951-1956.
 10. Blauth C, Schulenberg W, McCartney A, Taylor K, Loop F. Retinal microvascular studies in vivo with fluorescein angiography. *J Thorac Cardiovasc Surg* 1988;95:668-676.
 11. Schell R, Kern F, Greeley W, Schulman S, Frasco P, Croughwell N, Newman M, Reves J. Cerebral blood flow and metabolism during cardiopulmonary bypass. *Anesth Analg* 1993;76:849-865.
 12. Ono M, Arnaoutakis GJ, Fine DM, Brady K, Easley RB, Zheng Y, Brown C, Katz NM, Grams ME, Hogue CW. Blood Pressure Excursions Below the Cerebral Autoregulation Threshold During Cardiac Surgery are Associated With Acute Kidney Injury*. *Crit Care Med.* 2013;41(2):464-471.
 13. Ono M, Brady K, Easley R, Brown C, Kraut M, Gottesman R, Hogue CW. Duration and Magnitude of Blood Pressure Below Cerebral Autoregulation Threshold During Cardiopulmonary Bypass Is Associated With Major Morbidity And Operative Mortality. *J Thorac Cardiovasc Surg.* 2013;(in press).

35. OPTIMAL BLOOD PRESSURE DURING
CARDIOPULMONARY BYPASS DEFINED BY CEREBRAL
AUTOREGULATION MONITORING AND ITS
ASSOCIATION WITH SEVERE CORONARY ARTERY
DISEASE. Paper presented by Daijiro Hori,
M.D., Baltimore, Maryland.
E-mail: dougskgh05@gmail.com

Discussion by Kenneth G. Shann, CCP, LP,
Boston, Massachusetts.
E-mail: kshann@partners.org

Mr. K. Shann (Boston, Massachusetts):

Good afternoon. I would like to begin by
thanking the Association for the invitation to be
the discussant for this abstract presentation.
I'd also like to thank you, Dr. Hori, for allowing
me to review your manuscript prior to this session.

I'd also like to congratulate you and your
colleagues for a well-designed and well-executed
study. Intensive intraoperative cerebral
monitoring or brain monitoring in 614 patients is
a significant achievement. I'd also like to
recognize that this work compliments a very large
series of work from the group at Hopkins now focused

on the topic of cerebral autoregulation during cardiopulmonary bypass. This study does importantly highlight the differences in the autoregulation range between patients with coronary artery disease and those without and gives us insight into optimal targets for blood pressure management during cardiopulmonary bypass.

Ten days ago we celebrated the 63rd anniversary of the heart-lung machine, and after all this time we still have very limited data regarding the optimal blood pressure during cardiopulmonary bypass. So this work is also timely with the recent interest in creating strategies for goal-directed therapy for cardiopulmonary bypass.

So I have three questions for you. You've identified optimal blood pressure targets of 80 and 75 for patients with and without coronary artery disease. In addition, your work identified an additional 14% of patients whose lower limit of autoregulation was higher than 75 mmHg.

In some patients we know undergoing cardiopulmonary bypass, it is challenging to maintain empirical target arterial pressures from

our protocols and either elevated flow rates, elevated levels of vasopressors, or perhaps even transfusion is considered if not required.

I noticed in your methods you maintain CPB flow rates at 2.0 to 2.4 liters per minute per meters squared which are pretty consistent with common practice. I did not, however, see any context in your manuscript regarding the use of vasopressors to maintain a patient's pressure within their autoregulation range.

My first question is therefore related to vasopressor use. We know from previous laboratory work that phenylephrine may redirect blood flow away from the bowel and muscle and direct it to the brain and the liver.

In clinical practice, do we know whether strategies to maintain a patient's pressure within cerebral autoregulation range such as using increased pressors will ultimately improve outcome, or is it possible it causes other unwanted complications such as gut ischemia?

35. OPTIMAL BLOOD PRESSURE DURING
CARDIOPULMONARY BYPASS DEFINED BY
CEREBRAL AUTOREGULATION MONITORING AND
ITS ASSOCIATION WITH SEVERE CORONARY
ARTERY DISEASE. Response by Daijiro
Hori, M.D., Baltimore, Maryland.

DR. HORI: Yes, that is a good question,
and thank you for the good point.

We haven't looked at the other organ
ischemia, but as I have shown in the previous
slide, there is an association between the
incidence of AKI and the blood pressure
management. In our institution, majority of the
perfusionists change the pump flow first to control
the blood pressure. Then, they will use
phenylephrine to control the blood pressure.

Our previous studies have shown that the
blood pressures below the optimal mean arterial
pressure or that below the low limit of
autoregulation were associated with AKI, which
means that if the blood pressure is too low, the
incidence of AKI would go up. But we didn't look
at the dosage of phenylephrine in association with
AKI. That is something that we need to look at.

And the studies show that the blood pressures below the optimal mean arterial pressure or below the low limit of autoregulation were associated with AKI, which means that if the blood pressure is too low, the incidence of AKI would go up. But we didn't look at the dosage of phenylephrine in association with an AKI, so that's something that we need to look at.

MR. SHANN: Thank you.

To follow with that question, in 1995 the Cornell group randomized 248 patients undergoing cardiopulmonary bypass to either a blood pressure of 50 to 60 or 80 to 100. They reported improved outcomes in the high pressure group; however, this work received scrutiny in part because of the high stroke rate in the low pressure group of 7.2%.

Other work your group has done, which was referenced your manuscript, to study the association between autoregulation range and outcome has been observational without measurement of interventions. And I just ask you is it time to perform a randomized trial, kind of like the Cornell group did to answer the question do interventions to maintain a patient's pressure

within their autoregulation range during cardiopulmonary bypass improve outcome?

In other words, do we need to do that randomized control trial now using your work as the basis?

DR. HORI: This is another good point, and we are actually doing a randomized trial at Hopkins right now. If the patient is randomized to treatment, we will tell the perfusionist and the anesthesiologist the optimal MAP. They will try to control the pressure at that optimal MAP, and we're going to look at the results

MR. SHANN: Do you have an algorithm for the interventions?

DR. HORI: No. That's one of the limitations that we have.

MR. SHANN: And then, lastly, the optimal mean arterial pressure targets you have identified will keep approximately 75 to 80% of patients within their autoregulation range which leaves 20 to 25% of patients out of their autoregulation range.

In the current study, you utilized transcranial Doppler combined with mean arterial

pressure put into a data housing unit that calculates a mean velocity index and determines the upper and lower limits of autoregulation. For the majority of us in the room, that's not practical in routine clinical practice.

Your group has also published work using an investigational prototype device that you refer to as the near-infrared spectroscopy cerebral autoregulation monitor, which I don't believe has ever come to market.

You more recently published on the use of an ultrasound tag near-infrared spectroscopy autoregulation monitor that I believe is FDA approved.

So my question is how close are we to having a user friendly and clinically practical technology to monitor cerebral autoregulation during cardiopulmonary bypass?

DR. HORI: Well, I think cerebral oximetry is very easy to use. We just have to put the sensor stickers on your forehead.

If you use the ICM software, all we need to do is just plug in the NIRS signals into the ICM computer, and it will calculate the cerebral

oximetry index for you. So it's a very easy system to use.

It's not that complicated as I wrote in the manuscript. It's just one laptop and one INVOS, and you will have the data there.

MR. SHANN: So there is an application that --

DR. HORI: So the ICM software just calculates everything for you, right. The software is the most important thing.

MR. SHANN: Thank you very much. Excellent presentation.

35. OPTIMAL BLOOD PRESSURE DURING
CARDIOPULMONARY BYPASS DEFINED BY
CEREBRAL AUTOREGULATION MONITORING AND
ITS ASSOCIATION WITH SEVERE CORONARY
ARTERY DISEASE. Paper presented by
Daijiro Hori, M.D., Baltimore, Maryland.
E-mail: dougskgh05@gmail.com

Discussion by Gosta B. Pettersson, M.D.,
Ph.D., Cleveland, Ohio.
E-mail: petterg@ccf.org

Dr. G. Pettersson (Cleveland, Ohio):

This is, of course, a very important
topic. How do you distinguish between the global
and local cerebral perfusion issues? Do we have
any other ways of monitoring whether the brain is
adequately perfused and at risk?

What is the "reasonably safe
under-perfusion limit"?

35. OPTIMAL BLOOD PRESSURE DURING
CARDIOPULMONARY BYPASS DEFINED BY
CEREBRAL AUTOREGULATION MONITORING AND
ITS ASSOCIATION WITH SEVERE CORONARY
ARTERY DISEASE. Response by Daijiro
Hori, M.D., Baltimore, Maryland.

DR. HORI: You mean for the monitoring?

DR. PETTERSSON: How far below the
autoregulation limit can you go before you get
damage to the brain?

DR. HORI: Well, I'm not really sure
about that. We are not sure if there is a cut-off
value. But our studies have shown that the
magnitude of blood pressure management outside the
autoregulation range is positively correlated with
incidence of AKI and neurological complications.

DR. PETTERSSON: Is there any way of
studying it in advance so we could know?

DR. HORI: Know the limit you mean?

DR. PETTERSSON: So we could know the
autoregulation in the individual patient before he
goes to the OR.

DR. HORI: Well, it is difficult to
predict autoregulation range without monitoring.

To measure cerebral autoregulation using this system, You need data from wide range of blood pressure to draw the cerebral autoregulation curve.

But now, the ICM software can predict the optimal MAP by algorithm. So even if you only have few data, it will be able to draw that cerebral autoregulation curve by algorithm.